| Chemical Information | |
| Antiviral agent ID | DrugRepV_2973 | |
| Antiviral agent name | Doxycycline-Ribavirin | |
| Structural Information | |
| 2-D Structure is not available | 3-D Structure is not available |
| Clinical Information | |
|
Primary Indication (Clinical trial phases) | Approved
| |
| Biological Information | |
|
Primary Indication (Disease Category) | Infectious Disease
| |
|
Secondary Indication | Chikungunya virus (CHIKV) NA Clinical isolate of CHIKV (East/Central/South African genotype) |   |
|
Secondary Indication (Approaches) | Experimental | |
| Secondary Indication (Methods) | In-vitro | |
|
Secondary Indication (Model system) [cell lines/ animal models] | Vero
| |
|
Secondary Indication (Mode of viral infection) | Adsorption
| |
|
Secondary Indication (Viral titer) | 2 MOI
| |
|
Secondary Indication (Mode of drug delivery) | Culture
| |
|
Secondary Indication (Time of drug delivery) | Post infection (2 hours)
| |
|
Secondary Indication (Duration of drug delivery) | 72 hours
| |
|
Secondary Indication (Drug concentration) | 15 μM
| |
|
Secondary Indication (Cell based assay) | Plaque assay
| |
|
Secondary Indication (Change) | Decrease
| |
|
Secondary Indication (Type of Inhibition) | Percentage inhibition [ 91 % ] | |
|
Reference | Rothan HA, Bahrani H, Mohamed Z, Teoh TC, Shankar EM, Rahman NA, Yusof R..A combination of doxycycline and ribavirin alleviated chikungunya infection..PLoS One. 2015 May 13;10(5):e0126360. doi: 10.1371/journal.pone.0126360. eCollection 2015. PMID:25970853
|  |
|
Comment | Doxycycline exhibited significant anti-CHIKV activity that acts by impairing viral entry of Vero cells. Doxycycline+Ribavirin reduced viral infectivity and replication in infected cells.
| |